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The discontinuation of PAR-1 antagonist RWJ-58259 beyond use 
as a biological probe is most likely due to it’s short half-life in vivo. 
However, retention of significant in vivo activity beyond the point 
where most of the RWJ-58259 had been consumed implies the 
generation of an active metabolite. Herein we describe the 
biological activity of a predicted metabolite of RWJ-58259 and the 
synthesis of analogues designed to enhance the metabolic 
stability of RWJ-58259. 
The serine protease thrombin plays a central role in the 
coagulation cascade - one of the earliest responses to tissue 
injury and a vital part of the normal wound healing process.
1
 
The coagulation cascade is a sequence of protease activations. 
It is initiated as factors circulating in the bloodstream come 
into contact with tissue factor in the extravasculature, as a 
consequence of tissue injury. Thrombin is activated in the 
cascade by the cleavage of its zymogen, pro-thrombin, and 
proceeds to convert soluble fibrinogen into insoluble fibrin. 
Thrombin also promotes the crosslinking of fibrin to form a 
preliminary clot, to which activated platelets can adhere. 
Through activation of various other components of the 
coagulation cascade, thrombin has both positive and negative 
feedback mechanisms, which regulate the activation of the 
cascade and ultimately the amount of fibrin generated. 
Thrombin is thus a key component of the coagulation cascade. 
As well as its role in the coagulation cascade, thrombin is 
responsible for the activation of various cellular responses, the 
signalling for which has been identified as being mediated by 
transmembrane proteins known as protease-activated 
receptors (PARs).
2
 As their name suggests, PARs are activated 
as a result of interaction with certain proteases; this leads to 
cleavage of their unusually long extracellular N-terminus chain 
at a specific location, uncovering a unique sequence of amino 
acids, which in turn binds to the receptor activation site. This 
then triggers downstream cellular signalling mechanisms. 
Four PARs (i.e. PAR-1-4) have been discovered to date with 
PAR-1 recognised as the major thrombin receptor. PAR-1 
activation has been implicated in the progression of various 
diseases and as such has been investigated as a potential 
therapeutic target for antagonists.
3
 Since targeting PAR-1 
allows for the blockade of thrombin’s cellular actions without 
interfering with its wider role in the wound healing process, 
investigations have focused on the treatment of fibrosis and 
thrombosis where it is desirable to reduce, but not eliminate, 
the actions of thrombin. The result of investigations relating to 
thrombosis led to the development and FDA approval of PAR-1 
antagonist Vorapaxar, the active ingredient in Merck’s 
Zontivity
TM
.
4
  
RWJ-58259, developed by Johnson & Johnson, was one of 
the first PAR-1 selective antagonists with potency sufficient to 
compete with the intramolecular activation mechanism of the 
receptor.
5
 Several groups have reported the use of RWJ-58259 
to investigate the role of PAR-1 activation in various diseases 
and cell signalling mechanisms.
6-11 
Although RWJ-58259 was 
demonstrated to be effective as a selective PAR-1 antagonist, 
the compound was not progressed into clinical trials by the 
developers. This is likely due to its poor oral bioavailability and 
short half-life (t½). In a human liver microsomes assay 
RWJ-58259 was reported to have a t½ = 9.2 min and i.v. 
administration in rats gave a t½ = 19.2 min.
12
 Despite the 
reported pharmacokinetic issues, the compound has been 
successfully utilised as a biological probe in numerous studies 
and continues to provide a significant biological response even 
in in vivo studies.
 
This discrepancy between the observed and 
predicted activity led us to suspect that metabolites generated 
from the parent compound may be contributing towards the 
overall biological response.
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To probe potential metabolic sites, the structure of RWJ-
58259 was analysed by in silico screening using MetaSite 
software (Molecular Discovery Ltd) to determine the 
compound’s susceptibility to metabolism by the major 
cytochrome P450s involved with first-pass xenobiotic 
modification.
13
 Highlighted atoms in Fig. 1 show the predicted 
major sites of metabolism, these include the benzylic positions 
of the terminal benzylamine, the substituted indazole N-1 
position, and the 3-position of the pyrrolidine ring. The latter 
of these sites was deemed to be of particular interest since it 
has been reported in the literature that the major metabolites 
formed in a human liver microsomes assay involved 
hydroxylation and oxidation of the pyrrolidine ring.
12
 
As a result of these findings, the pyrrolidin-3-ol derivative 
of RWJ-58259 was proposed as a likely metabolite and 
consequently synthesised on the basis of a published route for 
the synthesis of RWJ-58259 (Schemes 1-3).
14,15
 To begin, amide 
coupling of Fmoc-Dbu(Boc)-OH with benzylamine, and 
subsequent Fmoc-deprotection afforded amine 1. Next, amine 
1 was coupled to Fmoc-3,4-diFPhe-OH, which following Fmoc-
deprotection generated left-hand side fragment 2 in 65% 
overall yield over the 4 steps (Scheme 1).  
For the right-hand side fragment, nitrosation of 
6-nitroindole with sodium nitrite under aqueous acidic 
conditions resulted in rearrangement to form 6-nitro-1H-
indazole-3-carbaldehyde. Reductive amination of this 
intermediate with the relevant pyrrolidine moiety, i.e. 
pyrrolidine for RWJ-58259 and pyrrolidin-3-ol for the 
metabolite, was achieved in the presence of a mild reducing 
agent. Subsequent N-alkylation followed by nitro reduction 
afforded the targeted substituted indazoles (3 & 4) in an 
overall yield of 18% & 28%, respectively (4 steps, Scheme 2). 
Urea coupling of dipeptide fragment 2 with indazole fragments 
3 & 4, followed by Boc-deprotection gave target compounds 7 
& 8 (RWJ-58259) in 19% & 53% overall yield, respectively (2 
steps, Scheme 3), after purification by preparative HPLC and 
lyophilisation from dilute HCl (aq). 
To evaluate the biological activity of the proposed 
metabolite in human lung fibroblasts, an intracellular calcium 
ion mobilisation downstream of thrombin-mediated PAR-1 
activation was measured. Following incubation of the cells 
with compound 7, PAR-1 was agonised by addition of thrombin 
(10 nM). A FLIPR instrument was utilised for the detection of 
fluorescence generated as a result of complexation of released 
cytosolic Ca
2+
 with the Fluo-4 NW dye.
16
 RWJ-58259 (8), a full 
antagonist of PAR-1, was used as the standard in the assay.  
Interestingly, compound 7 - a predicted metabolite of 
RWJ-58259 - demonstrated potency in a similar range to the 
parent compound; however, the activity was significantly 
LHS  RHS 
Figure 1 RWJ-58259 major sites of phase I metabolism as predicted by in silico 
screening using MetaSite; left-hand side (LHS) & right-hand side (RHS) fragments 
shown, which are referred to in the synthesis description 
Scheme 1 Reagents and conditions: a) HBTU, HOBt, DIPEA, DMF, BnNH2, 3 h; b) Et2NH, 
DMF, 2 h; c) HBTU, HOBt, DIPEA, Fmoc-3,4-diF-Phe-OH, DMF, 16 h 
Scheme 2 Reagents and conditions: a) NaNO2, HCl (6 M), 5 h; b) pyrrolidine or 3-OH/(S)-
3-F/(R)-3-F derivative, NaB(OAc)3H, CH2Cl2/DMF/AcOH (90:9:1), 3 h; c) 2,6-diClBnBr, 
Cs2CO3, THF, 20 h; d) FeCl3.6H2O, activated charcoal, Me2NNH2, MeOH, reflux, 5 h 
Scheme 3 Reagents and conditions: a) triphosgene, DMAP, THF, 2, 0-20 °C, 2 h; b) HCl 
(4 M) in 1,4 dioxane, 20 °C, 2 h 
Figure 2 Dose-inhibition curves for compound 7 and RWJ-58259 (8) versus thrombin (10 
nM) in a Ca2+ mobilisation assay 
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reduced with only 50% inhibition achieved compared to 
RWJ-58259 (Figure 2). This result, to the best of our 
knowledge, is the first example of a proposed metabolite of 
RWJ-58259 showing significant PAR-1 antagonist activity and 
confirms the possible role for metabolites in the overall 
biological activity demonstrated by RWJ-58259 in in vivo 
studies.  
It was reasoned, however, that increasing the metabolic 
stability of the parent compound would be favourable in order 
to maintain the full antagonist activity demonstrated in in vitro 
studies over a longer period. Our initial focus remained on the 
3-position of the pyrrolidine ring whereby a fluorine atom, a 
classical bioisostere for hydrogen, was incorporated to take 
advantage of the strong C-F bond with the intention of 
reducing oxidative metabolism occurring at this position.
17
 
Analogues 9 and 10 were synthesised following the same 
synthetic route as described for the synthesis of 7 except in 
that 3-F-pyrrolidine was used in the reductive amination step 
(Scheme 2).    
At this juncture, we also took the opportunity to expand 
our approach of blocking predicted sites of metabolism to 
include the benzylic positions highlighted in Fig. 1. Introduction 
of groups (e.g. Me, t-Bu) to increase steric hindrance at 
susceptible locations is a common strategy used to improve a 
molecule’s metabolic stability and increase t½.
18
 As such, 
analogues were synthesised with a methyl group incorporated 
in the terminal benzylamine by using the relevant 1-phenyl-
ethanamine for the first amide coupling reaction (Scheme 4), 
ultimately affording analogues 15 and 16 following urea 
coupling to indazole 4 (Scheme 5). This strategy was also used 
at the other benzylic position predicted as a major site of 
metabolism. To do this, 2,6-dichlorobenzaldehyde was reacted 
with a methyl Grignard reagent and the resulting secondary 
alcohol converted to the desired mesylate (17, see ESI for 
details) following treatment with methanesulfonyl chloride. 
This alkylating reagent was then used for the synthesis of 
indazole 18 (Scheme 6), ultimately leading to target compound 
19 (Scheme 7).  
Compounds 9, 10, 15, 16 & 19 were then tested for 
biological activity and pleasingly were mostly found to be of 
similar potency to RWJ-58259 (8, pIC50 of 6.5) with pIC50 values 
in the range of 6.3-6.6 (Table 1); compound 19 even 
demonstrated a slight increase in potency with a pIC50 of 7.1. 
Analogues 15, 16 & 19, with substituted benzylic positions, 
were shown to maintain full antagonist activity when 
compared to the activity of RWJ-58259. Interestingly, 
however, incorporating a fluorine atom at the 3-position of the 
pyrrolidine ring resulted in less than full antagonism for 
compounds 9 and 10. The reduced activity demonstrated for 
compounds 7, 9 & 10 infers that substitution of the pyrrolidine 
ring has a significant effect upon the compounds ability to fully 
block the binding of the sequence of amino acids uncovered 
following exposure to thrombin. Since a fluorine atom is of 
comparable size to that of a hydrogen atom, this trend is 
unlikely to be as a result of a steric effect. Instead this trend is 
likely to be a consequence of the influence of having an 
electronegative atom (F or O) near the nitrogen of the 
pyrrolidine ring, i.e. reducing the basicity of the nitrogen lone 
pair.
19
 
Table 1 pIC50 and activity data for antagonists of PAR-1 
Compound pIC50 Antagonist activity
a 
RWJ-58259 (8) 6.5 Full 
7 6.6 54% 
9 6.4 79% 
10 6.5 63% 
15 6.3 Full 
16 6.4 Full 
19 7.1 Full 
Scheme 7 Reagents and conditions: a) triphosgene, DMAP, THF, 2, 0-20 °C, 2 h; b) HCl 
(4 M) in 1,4 dioxane, 20 °C, 2 h 
Scheme 4 Reagents and conditions: a) HBTU, HOBt, DIPEA, DMF, (R)- or (S)-1-
phenylethanamine, 3 h; b) Et2NH, DMF, 2 h; c) HBTU, HOBt, DIPEA, Fmoc-3,4-diF-Phe-
OH, DMF, 16 h 
Scheme 5 Reagents and conditions: a) triphosgene, DMAP, THF, 13 or 14, 0-20 °C, 2 h; 
b) HCl (4 M) in 1,4 dioxane, 20 °C, 2 h 
Scheme 6 Reagents and conditions: a) NaNO2, HCl (6 M), 5 h; b) pyrrolidine or 
3-OH/(S)-3-F/(R)-3-F derivative, NaB(OAc)3H, CH2Cl2/DMF/AcOH (90:9:1), 3 h; c) 2,6-
diClBnBr or 1-(2,6-diClPh)EtOMs, CsCO3, THF, 20 h; d) FeCl3.6H2O, activated charcoal, 
Me2NNH2, MeOH, reflux, 5 h 
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a – compared to RWJ-58259 as standard 
To conclude, we have shown that a predicted metabolite of 
PAR-1 antagonist RWJ-58259 demonstrates similar potency to 
the parent compound in an in vitro Ca
2+
 mobilisation assay, 
though intrinsic activity was significantly reduced. To the best 
of our knowledge, this is the first time a proposed metabolite 
of RWJ-58259 has been proven to demonstrate PAR-1 
antagonist activity of similar potency to RWJ-58259. This result 
sheds some light on the reported in vivo activity of RWJ-58259 
despite its incredibly poor bioavailability. Analogues were 
synthesised with the intention of maintaining the potency and 
activity demonstrated by RWJ-58259, whilst increasing the 
metabolic stability of the administered compound using well 
known strategies for reducing metabolism. Several compounds 
were tested and shown to be full antagonists of PAR-1 and 
equipotent to RWJ-58259. We believe our findings suggest 
that analogues of RWJ-58259 targeted at blocking metabolism, 
such as compounds 9, 10, 15, 16 & 19, may lead to significantly 
enhanced bioactivity as a result of the administered compound 
remaining the major active ingredient for a longer period 
rather than a less efficacious metabolite. 
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